Targeted therapy market seen topping $157 billion by 2030

The targeted therapy market is projected to grow 8% annually and reach $157.2 billion by 2030, driven by precision oncology, biomarker testing and new drug approvals. North America is expected to remain the largest regional market as monoclonal antibodies and small molecules capture most of the category's growth.

Why it matters: - Targeted therapies are becoming a larger part of cancer care as health systems shift toward precision medicine and biomarker-driven treatment. - The category's growth points to continued investment in oncology drugs, diagnostics and next-generation biologics. - The market's expansion could influence pricing, R&D spending and competition across pharmaceutical and biotech companies.

What happened: - The Business Research Company projected the targeted therapy market will grow at an 8% CAGR and reach $157.2 billion by 2030. - The report said targeted therapies will make up about 36% of the $441 billion oncology drugs market in 2030. - The report said targeted therapies will represent close to 6% of the broader $2.496 trillion pharmaceuticals market by 2030. - The analysis was published in The Business Research Company's Targeted Therapy Global Market Report 2026. - F. Hoffmann-La Roche Ltd ranked as the top targeted therapy seller in 2025 with a 3% market share. - AstraZeneca also held a 3% share in 2025, while Novartis AG, Pfizer Inc, Merck & Co Inc, Bristol Myers Squibb and Daiichi Sankyo Company Limited each held 2%. - Eli Lilly and Company, Johnson & Johnson and Amgen Inc each held 1% in 2025.

The details: - The market breaks into two main product types: small molecule medicines and monoclonal antibodies. - Monoclonal antibodies are expected to be the largest segment by 2030, accounting for 60% of the market, or about $94 billion. - The market also spans hospital pharmacies, retail pharmacies and online pharmacies. - Major cancer applications include breast cancer, colorectal cancer, leukemia, lung cancer, lymphoma and renal cancer. - North America is forecast to remain the dominant region through 2030, reaching $63 billion from $46 billion in 2025. - North America is expected to grow at a 6% CAGR over the period. - The USA is forecast to be the largest national market, rising to $59 billion in 2030 from $42 billion in 2025. - The report said the top 10 companies accounted for 20% of revenue in 2025, showing a moderately fragmented market. - The report identified more than 20 leading companies, including Sanofi SA, Takeda Pharmaceutical Company Limited, Bayer AG, Gilead Sciences Inc and Biogen Inc. - The report also listed suppliers such as BASF SE, Merck KGaA and Thermo Fisher Scientific Inc., plus distributors including Cencora Inc., Cardinal Health Inc. and McKesson Corporation. - The report named major end users including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Mayo Clinic and Cleveland Clinic.

Between the lines: - The market's fragmentation suggests no single company controls the category, even as a few large drugmakers hold leading positions. - Growth is being pushed by more cancer diagnoses, broader use of genomic profiling and companion diagnostics, and a heavier focus on personalized oncology. - Investment is also flowing into monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, bispecific antibodies and targeted radiopharmaceuticals. - A July 2026 FDA approval for Celcuity Inc.'s REVTORPYK for HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer shows how new approvals can open narrower but more valuable patient segments. - The report estimated three growth drivers would contribute roughly 2.4%, 2.3% and 2.2% annual growth, respectively, from cancer prevalence, biomarker testing and biopharma R&D investment.

What's next: - The report expects monoclonal antibodies and small molecules to add more than $47 billion combined by 2030. - Monoclonal antibodies are projected to contribute $28 billion of that increase, while small molecules add $19 billion. - Future growth will likely depend on biomarker-specific therapies, combination regimens, antibody engineering and broader precision oncology approvals. - Companies are expected to keep expanding clinical pipelines, partnerships and biomarker-driven treatment strategies to defend share.

The bottom line: - Targeted therapy is moving from a niche oncology category to a core growth engine for drugmakers, diagnostics companies and cancer centers alike.